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女性専門外来における甲状腺乳頭癌の有病率と診断
過程についての後ろ向き解析
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Background: Non-specific complaints are common in women, and tend to be diagnosed as menopausal disor-
ders or autonomic imbalance without adequate examination. In Women Specific Clinic (WSC), we carry out a
careful differential diagnosis on the basis of patients’ complaints, taking account of women’s mental and physical
characteristics. One point that warrants particular attention is that many non-specific complaints resemble the
symptoms of thyroid dysfunction and malignant tumor (MT). Thyroid cancer (TC), 90 % of which is papillary thy-
roid carcinoma (PTC), is also about three times more common in women than in men. TC is commonly diagnosed
at a younger age than other adult-onset cancers, and the risk of TC peaks earlier in women than it does in men,
being highest in the 40s and 50s, around the age of menopause.
We therefore focused on MT and PTC as a common female cancer that often coincides with menopause, and
investigated the prevalence and attributes of patients diagnosed with PTC in our clinic as well as the diagnostic
process.
Materials and Methods:We investigated the prevalence and type of malignancy and the diagnostic process
for those patients diagnosed with PTC out of 668 patients who were first examined in WSC between June 2011
and June 2012.
Results: MT was identified in 6 of 668 patients (0.9 %) and PTC was identified in 4 of 668 patients (0.6 %) ex-
amined during this 1-year period. The attributes and complaints of these patients varied; the common factor was
the fact that the physician listened carefully to symptoms peripheral to the principal complaint and carried out
the appropriate investigation (ultrasonography) required for a differential diagnosis.
Conclusions: Women tend to experience a variety of menstruation-related and menopausal symptoms that
present as non-specific complaints. These may easily mask the symptoms of underlying disease such as PTC in
menopausal or premenopausal woman. At women’s medicine, health providers should be aware of this point and
conduct a careful differential diagnosis.
Key Words: non-specific complaints, menopause, papillary thyroid carcinoma, Women Specific Clinic, differential
diagnosis
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Table　1　Breakdown of six patients diag-
nosed with malignant tumor
Case Age Diagnosis
1 40 y.o thyroid papillary carcinoma
2 48 y.o thyroid papillary carcinoma
3 50 y.o thyroid papillary carcinoma
4 74 y.o thyroid papillary carcinoma
5 51 y.o Colorectal cancer
6 75 y.o Brain tumor (glioblastoma)
Table 1 shows the age and diagnosis with ma-
lignant tumor. (6 of 668 newly diagnosed pa-























































のうちの約 0.9％を占めた．その内訳を Table 1に
まとめた．甲状腺乳頭癌は 668名中 4名（約 0.6 %）
で，悪性腫瘍発見症例中，最多で当科での悪性腫瘍























Table　2　Breakdown of four patients diagnosed with papillary thyroid carcinoma
Case Age Chief complaints Diagnosis Points leading to diagnosis
1 40 y.o Fever except for menstruation last-






Family history of Basedow disease
2 48 y.o Palpitation, stiff shoulder, headache 
after the Great East Japan Earth-
quake
thyroid papillary carcinoma Thyroid peroxidase antibody, Thyroid 
microsomal antibody, Thyroid echo
3 50 y.o Chill, hot flas, multiple perspiration 
lasting 1 year
thyroid papillary carcinoma Latent Hypothyroidism
Thyroid echo
4 74 y.o Headache, dizziness, stiff shoulder 
lasting about 5 years
thyroid papillary carcinoma High Thyroglobulin
Thyroid echo
Table 2 shows the age, principal complaint, diagnosis, and points leading to the diagnosis of each patient diagnosed with papillary 
thyroid carcinoma. The patients presented with a wide variety of principal complaints.
ため頭部MRI，頸部 X線検査を受けたが，特に異














Hb 12.1 g/dl，Ht 42 %，Plt 21.3×104/ml，Alb 4.4
mg/dl，AST 12 IU/l，ALT 13 IU/l，γ-GTP 38 IU/
l，LDH 184 IU/l，BUN 17.6 mg/dl，Cr 0.65 mg/dl，
Na 131 mEq/l，K 4.0 mEq/l，T-cho 100 mg/dl，TG
86 mg/dl，FBS 100 mg/dl，FT3 2.6 pg/ml，FT4 1.11
ng/dl，TSH 1.81 μIU/ml，Tg 113 ng/ml，TgAb 15


































検査所見：WBC 68.6×103/ul（Neu 58.1 %，Eos
4.5 %），RBC 686×104/ul，Hb 13.2 g/dl，Ht 38.6 %，
Plt 29.8×104/ml，Alb 4.5 mg/dl，AST 26 IU/l，ALT
39 IU/l，γ-GTP 39 IU/l，LDH 218 IU/l，BUN 11 mg/
dl，Cr 0.73 mg/dl，Na 141 mEq/l，K 3.7 mEq/l，Cl
103 mEq/l，T-cho 177 mg/dl，LDL 63 mg/dl，HDL
41 mg/dl，TG 292 mg/dl，FBS 110 mg/dl，HbA1c
5.9 %，FT3 2.1 pg/ml，FT4 0.67 ng/dl，TSH 7.43
μIU/ml，Tg 2.6 ng/ml，TgAb 63 IU/ml，TPOAb
12
―54―
































検査所見：WBC 48.7×103/ul（Neu 52.5 %，Eos
5.3 %），RBC 402×104/ul，Hb 12.4 g/dl，Ht 36.7 %，
Plt 24.3×104/ml，Alb 4.1 mg/dl，AST 13 IU/l，ALT
11 IU/l，γ-GTP 16 IU/l，CK 106 IU/l，LDH 188 IU/
l，BUN 12.8 mg/dl，Cr 0.61 mg/dl，UA 4.4 mg/dl，
Na 142 mEq/l，K 3.8 mEq/l，Cl 102 mEq/l，T-cho
182 mg/dl，FBS 100 mg/dl，FT3 2.0 pg/ml，FT4
0.71 ng/dl，TSH 4.52 μIU/ml，Tg 23.3 ng/ml，TgAb




































検査所見：WBC 44.2×103/ul（Neu 60.2 %，Eos
1.1 %），RBC 410×104/ul，Hb 12.8 g/dl，Ht 36.3 %，
Plt 21.9×104/ml，Alb 4.5 mg/dl，AST 20 IU/l，ALT
17 IU/l，γ-GTP 28 IU/l，CK 78 IU/l，BUN 19.1 mg/
dl，Cr 0.84 mg/dl，UA 8.5 mg/dl，LDL 127 mg/dl，
HDL 49 mg/dl，TG 168 mg/dl，FBS 100 mg/dl，
HbA1c 5.3 %，FT3 2.5 pg/ml，FT4 0.89 ng/dl，TSH
3.11 μIU/ml，Tg 54.8 ng/ml，TgAb＜=10 IU/ml，






















































名中 4名（約 0.6 %）で，悪性腫瘍発見例の 66.6 %
を占めていた．全国の甲状腺癌の有病率は，女性で
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